Literature DB >> 28138632

A rare case of a primary hepatic neuroendocrine tumor.

Sajiv Sethi1, Prasad Kulkarni2.   

Abstract

Neuroendocrine tumors are well-differentiated low grade malignant neoplasms. Their pathogenesis is thought to be secondary to the unrestricted proliferation of neuroendocrine cells. They most commonly arise in the bronchopulmonary or gastrointestinal tract but can originate from almost any organ. While the liver is a common site of metastases, primary hepatic neuroendocrine tumors are an exceedingly rare pathology, of which fewer than 100 cases have been described in world literature. Thus, there exists a paucity of data regarding the clinical presentation, diagnosis and management of this disease. We present a case of a 35-year-old patient who presented to our facility for evaluation of a cough and cervical lymphadenopathy. Two biopsies of the lymph nodes were negative, however on workup for an occult malignancy a hypodense heterogeneous hypervascular lesion measuring 3.7 cm × 2.7 cm in segment IVb of the liver was noted on computer tomography (CT) scan. The levels of laboratory studies such as liver enzymes, alkaline phospatase, chromogranin A, 24-hour 5 hydroxyindoleacetic acid (5-HIAA) and tumor markers including alpha fetoprotein were not elevated. An MRI confirmed the mass, and the patient underwent CT guided biopsy of the hepatic lesion. Staining from the biopsy resulted in cells reactive for synaptophysin, chromogranin, anti-Cytokeratin (CAM 5.2), MOC31, CD 56 and mucin glycoprotein (MUC) confirming a nonsecretory neuroendocrine tumor. Patient underwent octreotide scan, PET scan, CT chest, MRI head along with EUS, EGD and colonoscopy to evaluate for a primary source, however, none was found. The well localized presentation without extensive hepatic invasion made the patient a candidate for surgical resection which was successfully performed. The patient remains disease free over 36 months after initial presentation. Primary hepatic neuroendocrine tumors are an exceedingly rare entity whose variable presentation necessitates provider familiarity with this condition. Once identified, excluding other primary locations with thorough investigation and treatment with surgical resection has been shown to provide the most patient benefit.

Entities:  

Keywords:  Hepatic lesion; neuroendocrine; solitary tumor

Year:  2016        PMID: 28138632      PMCID: PMC5244693          DOI: 10.21037/tgh.2016.06.07

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  13 in total

1.  Somatostatin Receptors in the Diagnosis and Therapy of Neuroendocrine Tumor.

Authors: 
Journal:  Oncologist       Date:  1997

Review 2.  Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report.

Authors:  Y P Le Treut; J R Delpero; B Dousset; D Cherqui; P Segol; G Mantion; L Hannoun; G Benhamou; B Launois; O Boillot; J Domergue; H Bismuth
Journal:  Ann Surg       Date:  1997-04       Impact factor: 12.969

3.  Long-term survival after surgical management of neuroendocrine hepatic metastases.

Authors:  Evan S Glazer; Jennifer F Tseng; Waddah Al-Refaie; Carmen C Solorzano; Ping Liu; Katherine A Willborn; Eddie K Abdalla; Jean-Nicolas Vauthey; Steven A Curley
Journal:  HPB (Oxford)       Date:  2010-08       Impact factor: 3.647

Review 4.  Long-term survival after resection for primary hepatic carcinoid tumor.

Authors:  Clayton D Knox; Christopher D Anderson; Laura W Lamps; R Benton Adkins; C Wright Pinson
Journal:  Ann Surg Oncol       Date:  2003-12       Impact factor: 5.344

5.  Aggressive surgery for metastatic liver neuroendocrine tumors.

Authors:  Jeffrey A Norton; Robert S Warren; Mary G Kelly; Marlene B Zuraek; Robert T Jensen
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

Review 6.  Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients.

Authors:  T Lehnert
Journal:  Transplantation       Date:  1998-11-27       Impact factor: 4.939

7.  Hepatic resection and transplantation for primary carcinoid tumors of the liver.

Authors:  Stephen W Fenwick; Judith I Wyatt; Giles J Toogood; J Peter A Lodge
Journal:  Ann Surg       Date:  2004-02       Impact factor: 12.969

8.  Giant hepatic carcinoid: a rare tumor with a favorable prognosis.

Authors:  Serge Landen; Maxime Elens; Celine Vrancken; Frederiek Nuytens; Thibault Meert; Veronique Delugeau
Journal:  Case Rep Surg       Date:  2014-02-09

9.  Primary hepatic carcinoid tumor: a case report and review of the literature.

Authors:  Chih-Wen Lin; Chung-Hsu Lai; Chia-Chang Hsu; Chao-Tien Hsu; Pei-Min Hsieh; Kuo-Chen Hung; Yaw-Sen Chen
Journal:  Cases J       Date:  2009-01-27

Review 10.  Anatomic and functional imaging of metastatic carcinoid tumors.

Authors:  Andrew F Scarsbrook; Arul Ganeshan; Jane Statham; Rajesh V Thakker; Andrew Weaver; Denis Talbot; Philip Boardman; Kevin M Bradley; Fergus V Gleeson; Rachel R Phillips
Journal:  Radiographics       Date:  2007 Mar-Apr       Impact factor: 5.333

View more
  2 in total

1.  Primary hepatic neuroendocrine tumour masquerading as a giant haemangioma: an unusual presentation of a rare disease.

Authors:  Talal Almas; Faisal Inayat; Maryam Ehtesham; Muhammad Kashif Khan
Journal:  BMJ Case Rep       Date:  2020-09-08

Review 2.  Primary hepatic neuroendocrine tumor with multiple liver metastases: A case report with literature review.

Authors:  Yijun Xia; Lei Zhang; Huijun Wu; Liang Qiao; Long Xia
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.